Cost-effectiveness of hepatitis C virus test-and-treat and risk reduction strategies among men who have sex with men living with HIV in France.
Mathieu CastryAnthony CousienKaren ChampenoisVirginie SupervieAnnie VelterJade GhosnYazdan YazdanpanahA David PaltielSylvie Deuffic-BurbanPublished in: Journal of the International AIDS Society (2022)
In the French context, current HCV screening practices without risk reduction among MSM living with HIV cannot be justified on economic grounds. Risk reduction interventions targeted to high-risk individuals-alongside screening either once or twice a year-could be cost-effective depending on the policymaker's willingness-to-pay.